Search research articles
Contact Us
Filters
Showing results (261-270 of 294) with videos related to
Page
of 30
Sort By:
The Lancet Regional Health. Europe
|
January 10, 2022
The benefits, costs and feasibility of a low incidence COVID-19 strategy
Thomas Czypionka, Emil N Iftekhar, Barbara Prainsack, et al.
JCI Insight
|
August 1, 2024
Focusing HIV-1 Gag T cell responses to highly conserved regions by DNA vaccination in HVTN 119
Spyros A Kalams, Barbara K Felber, James I Mullins, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
July 1, 2009
Differential association of programmed death-1 and CD57 with ex vivo survival of CD8+ T cells in HIV infection
Constantinos Petrovas, Benjamin Chaon, David R Ambrozak, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
June 24, 2005
Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell help
Michele A Kutzler, Tara M Robinson, Michael A Chattergoon, et al.
British Journal of Cancer
|
April 14, 2015
Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer
K L Mahon, H-M Lin, L Castillo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2025
Alectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: final overall survival analysis of the phase III ALEX study
S Peters, R Camidge, R Dziadziuszko, et al.
Plos One
|
April 5, 2013
HIV-1 p24(gag) derived conserved element DNA vaccine increases the breadth of immune response in mice
Viraj Kulkarni, Margherita Rosati, Antonio Valentin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 9, 2015
A phase III randomized trial of adding topical nitroglycerin to first-line chemotherapy for advanced nonsmall-cell lung cancer: the Australasian lung cancer trials group NITRO trial
A Davidson, A-S Veillard, A Tognela, et al.
Plos One
|
January 13, 2012
CTL responses of high functional avidity and broad variant cross-reactivity are associated with HIV control
Beatriz Mothe, Anuska Llano, Javier Ibarrondo, et al.
Human Vaccines & Immunotherapeutics
|
July 2, 2013
Comparison of intradermal and intramuscular delivery followed by in vivo electroporation of SIV Env DNA in macaques
Viraj Kulkarni, Margherita Rosati, Jenifer Bear, et al.
Page
of 30
Search research articles
Search
Showing results (261-270 of 294) with videos related to
Sort By:
Page
of 30
The Lancet Regional Health. Europe
|
January 10, 2022
The benefits, costs and feasibility of a low incidence COVID-19 strategy
Thomas Czypionka, Emil N Iftekhar, Barbara Prainsack, et al.
JCI Insight
|
August 1, 2024
Focusing HIV-1 Gag T cell responses to highly conserved regions by DNA vaccination in HVTN 119
Spyros A Kalams, Barbara K Felber, James I Mullins, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
July 1, 2009
Differential association of programmed death-1 and CD57 with ex vivo survival of CD8+ T cells in HIV infection
Constantinos Petrovas, Benjamin Chaon, David R Ambrozak, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
June 24, 2005
Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell help
Michele A Kutzler, Tara M Robinson, Michael A Chattergoon, et al.
British Journal of Cancer
|
April 14, 2015
Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer
K L Mahon, H-M Lin, L Castillo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2025
Alectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: final overall survival analysis of the phase III ALEX study
S Peters, R Camidge, R Dziadziuszko, et al.
Plos One
|
April 5, 2013
HIV-1 p24(gag) derived conserved element DNA vaccine increases the breadth of immune response in mice
Viraj Kulkarni, Margherita Rosati, Antonio Valentin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 9, 2015
A phase III randomized trial of adding topical nitroglycerin to first-line chemotherapy for advanced nonsmall-cell lung cancer: the Australasian lung cancer trials group NITRO trial
A Davidson, A-S Veillard, A Tognela, et al.
Plos One
|
January 13, 2012
CTL responses of high functional avidity and broad variant cross-reactivity are associated with HIV control
Beatriz Mothe, Anuska Llano, Javier Ibarrondo, et al.
Human Vaccines & Immunotherapeutics
|
July 2, 2013
Comparison of intradermal and intramuscular delivery followed by in vivo electroporation of SIV Env DNA in macaques
Viraj Kulkarni, Margherita Rosati, Jenifer Bear, et al.
Page
of 30